Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Deals

Grand Pharmaceutical Group Expands Distribution Partnership with Sirtex Medical in China

Fineline Cube Nov 18, 2024

Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...

Company Deals

Keymed Biosciences Enters Global Licensing Agreement with Platina Medicines for CM336

Fineline Cube Nov 18, 2024

Keymed Biosciences Inc., a China-based biopharmaceutical company (HKG: 2162), has announced a significant licensing agreement...

Company Drug

CanSino Biologics Initiates Phase I Clinical Trial for Freeze-Dried Hib Conjugate Vaccine

Fineline Cube Nov 18, 2024

China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced the commencement of a Phase I...

Company Deals

Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments

Fineline Cube Nov 18, 2024

Hangzhou Jiuyuan Gene Engineering Co., Ltd. has announced that it has successfully passed the listing...

Company Deals

NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology

Fineline Cube Nov 18, 2024

China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership...

Company Deals

Shanghai’s Matwings Secures Over $13.8 Million in Series A Financing for AI Protein Design

Fineline Cube Nov 18, 2024

Matwings, an AI-based protein design service provider headquartered in Shanghai, has announced the successful completion...

Company Drug

EMA’s CHMP Recommends Approval for MSD’s Keytruda Combo in Mesothelioma Treatment

Fineline Cube Nov 18, 2024

Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced...

Company Drug

EMA’s CHMP Recommends Approval for BMS’s Opdivo/Yervoy Combo in mCRC

Fineline Cube Nov 18, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Deals

Boston Scientific Expands Neuromodulation Portfolio with Axonics Acquisition

Fineline Cube Nov 18, 2024

Boston Scientific Corporation (NYSE: BSX), a leading player in the medical device industry, has announced...

Company Drug

Sandoz Receives EC Approval for Biosimilar to Eylea for Retinal Diseases

Fineline Cube Nov 18, 2024

Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced that it has received marketing approval from...

Company Medical Device

Peijia Medical Achieves First Compassionate Use of Taurus Trio TAVR System in Hong Kong

Fineline Cube Nov 18, 2024

Peijia Medical Ltd (HKG: 9996), a leading medical device company, has announced the completion of...

Company Drug

Sanofi’s Dupixent sBLA for Chronic Spontaneous Urticaria Accepted by FDA for Review

Fineline Cube Nov 18, 2024

French pharmaceutical giant Sanofi has announced that the US Food and Drug Administration (FDA) has...

Company Drug

Novo Nordisk Launches Semaglutide for Weight Management in China

Fineline Cube Nov 18, 2024

Denmark-based healthcare giant Novo Nordisk A/S (NYSE: NVO) has announced the official market launch of...

Company Drug

Sichuan Kelun-Biotech Secures NMPA Approval for Two Antibody Drug Conjugates

Fineline Cube Nov 18, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a leading biopharmaceutical company based in China, has...

Company Drug

Exegenesis Bio’s Gene Therapy EXG110 Earns Orphan Drug Status for Fabry Disease

Fineline Cube Nov 18, 2024

Exegenesis Bio, a leading provider of epigenetics experimental and analytical services headquartered in Hangzhou, has...

Company Deals

Shenzhen Weiguang Biological Partners with SUAT to Boost Life Science and Health Industry

Fineline Cube Nov 18, 2024

Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a prominent blood products manufacturer in China,...

Company Drug

Janssen-Cilag’s Lazcluze-Rybrevant Combo Receives Positive EMA Opinion for NSCLC Treatment

Fineline Cube Nov 18, 2024

Janssen-Cilag International NV, a subsidiary of the US pharmaceutical giant Johnson & Johnson (J&J; NYSE:...

Company Drug

Shanghai Junshi Biosciences’ Toripalimab Wins UK Approval for Nasopharyngeal and Oesophageal Cancers

Fineline Cube Nov 18, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...

Company Deals

C-Ray Therapeutics Secures Over $100 Million in Series A+ Financing for Radiopharmaceuticals

Fineline Cube Nov 18, 2024

C-Ray Therapeutics, a specialist in radiopharmaceuticals headquartered in Chengdu, has announced the successful completion of...

Company

BioNTech Acquires Biotheus for $800 Million, Enhancing Oncology Pipeline

Fineline Cube Nov 17, 2024

BioNTech (NASDAQ: BNTX), the biotech giant recognized for its role in developing the COVID-19 vaccine,...

Posts pagination

1 … 260 261 262 … 661

Recent updates

  • Kexing Pharmaceutical Launches HKEX Secondary Offering – Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline
  • Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer
  • Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations
  • BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year
  • Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Kexing Pharmaceutical Launches HKEX Secondary Offering – Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline

Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Others

Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations

Company

BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.